Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Open Access
- 17 July 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 71 (10), 2713-2722
- https://doi.org/10.1093/jac/dkw239
Abstract
During the last decade infections caused by MDR Gram-negative bacteria (GNB) have become increasingly prevalent. Because of their high morbidity and mortality rates, these infections constitute a serious threat to public health worldwide. Ceftazidime/avibactam is a new approved agent combining ceftazidime and a novel β-lactamase inhibitor with activity against various β-lactamases produced by MDR GNB. Avibactam has a spectrum of inhibition of class A and C β-lactamases, including ESBLs, AmpC and Klebsiella pneumoniae carbapenemase (KPC) enzymes. Thus, combination with this inhibitor expands ceftazidime's spectrum of activity to MDR Enterobacteriaceae and Pseudomonas aeruginosa strains. In Phase II clinical trials of patients with complicated intra-abdominal infections and complicated urinary tract infections ceftazidime/avibactam exhibited clinical efficacy comparable to those of meropenem and imipenem/cilastatin, respectively. A Phase III clinical trial confirmed the efficacy of ceftazidime/avibactam in patients with MDR Enterobacteriaceae and P. aeruginosa infections. Microbiological surveillance studies, in vivo animal models of infection and pharmacokinetic/pharmacodynamic target attainment analyses are also discussed, to assess the potential role of this new drug in the treatment of infections caused by MDR GNB.Keywords
This publication has 40 references indexed in Scilit:
- Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniaeClinical Microbiology & Infection, 2016
- Deaths Attributable to Carbapenem-ResistantEnterobacteriaceaeInfectionsEmerging Infectious Diseases, 2014
- Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of CarbapenemsAntimicrobial Agents and Chemotherapy, 2014
- ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patientsClinical Microbiology & Infection, 2013
- Successful Ertapenem-Doripenem Combination Treatment of Bacteremic Ventilator-Associated Pneumonia Due to Colistin-Resistant KPC-Producing Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2013
- Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010Infection Control & Hospital Epidemiology, 2013
- Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination TherapyClinical Infectious Diseases, 2012
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences of the United States of America, 2012
- Surveillance and management of multidrug-resistant microorganismsExpert Review of Anti-infective Therapy, 2011
- Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?Clinical Microbiology & Infection, 2011